Germline CDKN2A mutation implicated in predisposition to multiple myeloma

David Dilworth, Ling Liu, A. Keith Stewart, James R. Berenson, Norman Lassam, David Hogg

Research output: Contribution to journalArticle

44 Scopus citations

Abstract

Germline mutations of the CDKN2A (p16(INK4A)) tumor suppressor gene predispose patients to melanoma and pancreatic carcinoma. In contrast, mutations of the murine CDKN2A gene predispose BALB/c mice to pristane- induced plasmacytoma. We describe here a family in which a germline mutation of CDKN2A is present in 4 individuals who developed melanoma as well as in a fifth family member who is suffering from multiple myeloma. To determine whether the CDKN2A mutation predisposed the myeloma patient to her disease, we carried out loss of heterozygosity studies on sorted bone marrow from this individual and observed loss of the wild type CDKN2A allele in the malignant plasma cells. We suggest that germline mutations of CDKN2A may predispose individuals to a wider variety of malignancy than has been hitherto reported, but that the expression of these cancers may depend heavily on the genetic background of the patient. (C) 2000 by The American Society of Hematology.

Original languageEnglish (US)
Pages (from-to)1869-1871
Number of pages3
JournalBlood
Volume95
Issue number5
StatePublished - Mar 1 2000

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Dilworth, D., Liu, L., Stewart, A. K., Berenson, J. R., Lassam, N., & Hogg, D. (2000). Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood, 95(5), 1869-1871.